Geisinger president and CEO to make announcement at HLTH Conference
,
Dr. David T. Feinberg to unveil new information regarding Geisinger's DNA sequencing community health initiative
DANVILLE, Pa. – David T. Feinberg, M.D., MBA, Geisinger president and CEO, will make a major announcement during his presentation at the HLTH Conference, on May 6 at the Aria in Las Vegas. Dr. Feinberg’s presentation, “What Really Matters,” delves into the importance of DNA sequencing and looks at how genomic codes as well as zip codes can affect a person’s health.
Capping off the presentation will be a major announcement regarding Geisinger’s next steps when it comes to precision health.
“We think it’s time to transition our successful genomics program beyond the realm of research and into routine clinical care for all of our patients,” Dr. Feinberg said.
Geisinger is considered a leader in precision medicine with the success of its MyCode Community Health Initiative, which has enrolled more than 200,000 patient-participants and is delivering medically relevant results to participants and their primary care doctors. Some Geisinger participants have had cancers detected earlier and heart disease identified, allowing doctors to treat these conditions before any clinical symptoms became present.
“We're one of the only organizations taking a population approach to genomics through our MyCode project,” said Dr. Feinberg. “To me, what we’re doing is really anticipatory medicine. It's coming up with medically actionable results and giving that information back to our patients.”
Geisinger’s pioneering efforts in conducting large-scale DNA sequencing have garnered international recognition. In 2014, Geisinger announced a major collaboration with Regeneron Pharmaceuticals to sequence the DNA of its MyCode participants. Geisinger’s decision in 2013 to report clinically actionable genomic results to research participants was the first large-scale genomics project. Five years later, other large national and international projects are now just getting started.
“No other health system is doing exome sequencing on this scale, and no one has the experience with clinical reporting of actionable genomic results that we now have,” Dr. Feinberg added.
HLTH is a four-day event that brings together the most innovative and disruptive companies, ideas, and solutions with those in the industry who are prepared to advance the quality of care, improve patient experience, and revitalize the aging healthcare infrastructure. Dr. Feinberg will deliver his presentation Sunday at 6:20 p.m.
Capping off the presentation will be a major announcement regarding Geisinger’s next steps when it comes to precision health.
“We think it’s time to transition our successful genomics program beyond the realm of research and into routine clinical care for all of our patients,” Dr. Feinberg said.
Geisinger is considered a leader in precision medicine with the success of its MyCode Community Health Initiative, which has enrolled more than 200,000 patient-participants and is delivering medically relevant results to participants and their primary care doctors. Some Geisinger participants have had cancers detected earlier and heart disease identified, allowing doctors to treat these conditions before any clinical symptoms became present.
“We're one of the only organizations taking a population approach to genomics through our MyCode project,” said Dr. Feinberg. “To me, what we’re doing is really anticipatory medicine. It's coming up with medically actionable results and giving that information back to our patients.”
Geisinger’s pioneering efforts in conducting large-scale DNA sequencing have garnered international recognition. In 2014, Geisinger announced a major collaboration with Regeneron Pharmaceuticals to sequence the DNA of its MyCode participants. Geisinger’s decision in 2013 to report clinically actionable genomic results to research participants was the first large-scale genomics project. Five years later, other large national and international projects are now just getting started.
“No other health system is doing exome sequencing on this scale, and no one has the experience with clinical reporting of actionable genomic results that we now have,” Dr. Feinberg added.
HLTH is a four-day event that brings together the most innovative and disruptive companies, ideas, and solutions with those in the industry who are prepared to advance the quality of care, improve patient experience, and revitalize the aging healthcare infrastructure. Dr. Feinberg will deliver his presentation Sunday at 6:20 p.m.
About Geisinger
Geisinger is committed to making better health easier for the more than 1 million people it serves. Founded more than 100 years ago by Abigail Geisinger, the system now includes 10 hospital campuses, a health plan with more than half a million members, a research institute and the Geisinger College of Health Sciences, which includes schools of medicine, nursing and graduate education. With more than 25,000 employees and 1,700+ employed physicians, Geisinger boosts its hometown economies in Pennsylvania by billions of dollars annually. Learn more at geisinger.org or connect with us on Facebook, Instagram, LinkedIn and Twitter.
